Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB1901 in Relapsed or Refractory T-Cell Lymphoma
NCT04712864Phase 1Active, not recruiting
- Sponsor
- Legend Biotech Corporation
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB1901 in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Legend Biotech Corporation. Primary endpoints: Safety and Tolerability of LB1901 up to 2 years, Optimal Dose or Recommended Dose for Expansion (RDE) up to 2 years and 1 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
LB1901
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT04712864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712864.